Global expansion RoukenBio recently expanded its discovery center in Motherwell, Scotland and extended facilities into the United Kingdom, Northern Europe, and Europe, signaling opportunities to offer expanded CRO capabilities and local partnerships for clients with multi-region projects.

Diverse therapeutic focus The company works across inflammation, auto-immunity, immuno-oncology and oncology, including antibodies, cell therapies, nanoparticles, small molecules, protein degraders, peptides, recombinant proteins, vaccines and antibody drug conjugates, suggesting cross-domain collaboration potential with biotherapeutic developers seeking integrated in vitro discovery and safety assessments.

IndEx-2 platform RoukenBio markets a unique inducible cell line platform, IndEx-2, to recreate disease states more faithfully, presenting a differentiator for clients needing premium, custom assay development and early discovery data to de-risk programs.

Global customer base With customers in over 27 countries and a broad service scope from early discovery to GMP-ready potency assays, there is a strong opportunity to upsell expanded regulatory-ready studies, translational partners, and multi-country CRO engagements.

Health of business Reported revenue between one and ten million dollars indicates a growth-ready startup CRO with potential for scale via expanded services, higher-value assays, and strategic collaborations with larger CROs or biotech sponsors seeking flexible, collaborative partnerships.